Basic Searches
Searches without any special characters (listed below) will return items that contain the exact value(s) entered in the search field. This means that searching for "ASPIRIN CALCIUM" won't return any items that have "ASPIRIN GLYCINE CALCIUM" because the search term doesn't match exactly.
Boolean Operators
OR - searches with terms separated by " OR " will return items that contain any of the terms in the search.
Example: "ASPIRIN" OR "CALCIUM" will return items that have strings like "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because they contain at least one of the terms in the search.

AND - searches with terms separated by " AND " will return items that contain all the terms in the search.
Example: "ASPIRIN" AND "CALCIUM" won't return items that have strings "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because neither contain both terms, but it will return "ASPIRIN GLYCINE CALCIUM" because it contains both search terms.
version 2.7.1
Substance Class Protein
Protein Type RECEPTOR
Protein Sub Type
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
G9XQ9S7T2F
Record Status Validated
Record Version
Show Definitional References Hide Definitional References
Download
Name Type Language Details Access References
D(3) DOPAMINE RECEPTOR
Common Name
English  
DOPAMINE D3 RECEPTOR
Common Name
English  
Code System Code Type Description Access References
FDA UNII
G9XQ9S7T2F
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
PRIMARY
From To
1_103 1_181
1_355 1_358
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_12
N 1_19
N 1_97
N 1_173
Related Record Type Details Access References
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
INHIBITOR
Ki
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
PARTIAL AGONIST->TARGET
none
Mediator Substance Details
none
Most of the clinically used antipsychotics display fairly high affinity for D3 receptors in vitro, they lack significant D3 receptor binding in vivo. They also do not occupy D3 receptors in schizophrenic patients at clinically-relevant doses, despite having significant and expected D2 receptor occupancy. The lack of in vivo D3 receptor occupancy of currently used antipsychotics may be due to their inability to displace endogenous DA from these sites; especially since DA has approximately 20- fold higher affinity for D3 vs D2 receptors and D3 (but not D2) receptors exist predominantly in a high affinity state for DA”
Ki
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
Ki
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
INHIBITOR
Ki
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
INHIBITOR -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
MAJOR
Ki
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
PARTIAL AGONIST
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
PARTIAL AGONIST->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
RADIOLIGAND->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
ANTAGONIST->TARGET
Mediator Substance Details
none
ANTAGONIST
Ki
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
AGONIST -> TARGET
Mediator Substance Details
none
Emax 82% Transfected CHO cells
EC50
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
PARTIAL AGONIST->TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
AGONIST -> TARGET
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
INHIBITOR -> TARGET
Mediator Substance Details
none
ANTAGONIST
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
AGONIST -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:52:13 EDT 2021 , Edited by admin on Wed Aug 04 01:52:13 EDT 2021
Name Property Type Amount Referenced Substance Defining Parameters Access References
MOL_WEIGHT CHEMICAL
0
Created Wed Aug 04 01:52:13 EDT 2021
Created By admin
Last Edited Wed Aug 04 01:52:13 EDT 2021
Last Edited By admin
Index Source Text / Citation Source Type Tags Date Accessed File Access
1 WIKI WIKI PUBLIC_DOMAIN_RELEASE
2 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
3 dump-public-2021-07-22_UPDATED.gsrs BATCH_IMPORT Wed Aug 04 01:52:11 EDT 2021
4 https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022192lbl.pdf NDA PUBLIC REVIEW PUBLIC_DOMAIN_RELEASE
5 Svenningsson, Per, et al. "Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial." npj Parkinson's Disease 4.1 (2018): 35. JA
6 UNIPROT UNIPROT NOMEN
7 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
8 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
9 Feng, Meihua Rose, Joseph Loo, and Jonathan Wright. "Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome p450 2D6 extensive metabolizers: Species comparison and allometric scaling." Drug metabolism and disposition 26.10 (1998): 982-988. JA PUBLIC_DOMAIN_RELEASE
10 WIK WIKI NOMEN PUBLIC_DOMAIN_RELEASE
11 Corena-McLeod, Maria. "Comparative pharmacology of risperidone and paliperidone." Drugs in R&D 15.2 (2015): 163-174. JA
12 https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf FDA APPROVED DRUG LABEL PUBLIC_DOMAIN_RELEASE
13 https://www.drugbank.ca/drugs/DB00714#BE0000581 WEBSITE
14 WIK WIKI PUBLIC_DOMAIN_RELEASE NOMEN
15 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
16 Corena-McLeod, Maria. "Comparative pharmacology of risperidone and paliperidone." Drugs in R&D 15.2 (2015): 163-174. JA
17 WIKI WIKI NOMEN PUBLIC_DOMAIN_RELEASE
18 Corena-McLeod, Maria. "Comparative pharmacology of risperidone and paliperidone." Drugs in R&D 15.2 (2015): 163-174. JA
19 WIK WIKI NOMEN PUBLIC_DOMAIN_RELEASE
20 Attkins, Neil, et al. "Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human." Xenobiotica 40.11 (2010): 730-742. JA NOMEN PUBLIC_DOMAIN_RELEASE PHARMACOKINETICS
21 https://pubchem.ncbi.nlm.nih.gov/compound/Metopimazine#section=Biological-Test-Results PUBCHEM POT
22 Wager, Travis T., et al. "Dopamine D3/D2 receptor antagonist PF-4363467 attenuates opioid drug-seeking behavior without concomitant D2 side effects." ACS chemical neuroscience 8.1 (2016): 165-177. JA NOMEN POT PUBLIC_DOMAIN_RELEASE
23 http://www.uniprot.org/uniprot/P35462 SRS NOMEN PUBLIC_DOMAIN_RELEASE